Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivorximab plus metronomic chemotherapy for advanced or metastatic squamous NSCLC after ≥2nd-line failure
ChiCTR2500106870Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jul 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in Pulmonary squamous cell carcinoma, sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-Free Survival. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2500106870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106870.